When was Microbix founded?

Microbix was founded in 1988 and raised its 1st funding round 21 years after it was founded.

Where is Microbix located?

Microbix is headquartered in Mississauga, Canada.

How many employees does Microbix have?

As of Aug 31, 2026, the latest employee count at Microbix is 110.

Is Microbix a funded company?

Microbix is a funded company, having raised an undisclosed amount across 10 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Sep 23, 2009.

When was the latest funding round of Microbix?

Microbix's latest funding was a $***** Grant (prize money) round on Mar 20, 2023, with participation from 1 investor.

Where does Microbix rank among its competitors?

Microbix ranks 114th amongst 1952 active competitors, of which 450 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Microbix?

Microbix's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Microbix - 2026 Company Profile, Funding & Competitors

Company Details

Developer of various biological products and technological solutions. The company has expertise in virology and protein biochemistry. The Company developed a pipeline of selected biological technologies including VIRUSMAX (Influenza Virus Yield Enhancement Technology), LumiSort (Semen Sexing Technology), and the thrombolytic drug, Kinlytic (Urokinase). The company's core focus is in Infectious Disease Antigen, including cell culture, molecular biology, and others.

Website: microbix.com
Social
Email ID: *****@microbix.com
Phone Number: +1 **********

Key Metrics

Founded Year

1988

Location

Mississauga, Canada

Stage

Public

Latest Funding Round

Grant (prize money), Mar 20, 2023, $*****

Investors

Ontario Canada

Ranked

114^th among 1952 active competitors

Employee Count

110 as on Aug 31, 2026

Similar Companies

Antheia & 2658 more

Exit Details

Public

View Microbix's full profile

Microbix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Microbix Biosystems Inc. CIN: 1472866 , United States, Active		$5M - $25M (As on Jul 21, 2021)	-	-

Microbix got listed on Oct 01, 1992.

Click here to take a look at Microbix's IPO in detail

Microbix has raised funding over 10 rounds. Its first funding round was on Sep 23, 2009. Its latest funding round was a Grant (prize money) round on Mar 20, 2023 for $*****. 1 investor participated in its latest round. Microbix has 1 institutional investor.

Here is the list of recent funding rounds of Microbix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 20, 2023	1393989	Grant (prize money)	2569910	3598750	1525170	1594335
May 19, 2021	5294851	Post IPO	8836074	3922466	7451407	4229671
Jan 31, 2020	5366001	Post IPO	4085365	2886813	4149070	8499681

Access funding benchmarks and valuations. Sign up today!

View details of Microbix's funding rounds and investors

Microbix's employee count trend

Microbix has 110 employees as of Aug 26. Here is Microbix's employee count trend over the years:

Uncover Microbix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Microbix include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Microbix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
8th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	61/100
114th	Microbix 1988, Mississauga (Canada), Public	Developer of various biological products and technological solutions	-	Ontario Canada	48/100